RKIP has been described as an inhibitor of EMT and cancer metastasis, is found at low levels in many cancer types and associated with worse prognosis, and serves as a regulator of several significant transcription factors, all of which suggest that RKIP has tremendous potential for personalized precision medicine. This evidence concerns the gene PEBP1 and cancer.